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Background. Natural killer (NK) cells can rapidly respond to transformed and stressed cells, 
and represent an important effector cell type for adoptive immunotherapy. In addition to 
donor-derived primary NK cells, continuously expanding cytotoxic cell lines such as NK-92 
are also being developed for clinical applications. Methods. To enhance their therapeutic 
utility for the treatment of B-cell malignancies, we engineered NK-92 cells by lentiviral gene 
transfer to express chimeric antigen receptors (CARs) that target CD19 and contain human 
CD3z (CAR 63.z) or composite CD28-CD3z or CD137-CD3z signaling domains (CARs 
63.28.z and 63.137.z). Results. Exposure of CD19-positive targets to CAR NK-92 cells 
resulted in formation of conjugates between NK and cancer cells, NK-cell degranulation and 
selective cytotoxicity towards established B-cell leukemia and lymphoma cells. Likewise, the 
CAR NK cells displayed targeted cell killing of primary pre-B-ALL blasts that were resistant to 
parental NK-92. While all three CAR NK-92 cell variants were functionally active, NK-
92/63.137.z cells were less effective than NK-92/63.z and NK-92/63.28.z in cell killing and 
cytokine production, pointing towards differential effects of the costimulatory CD28 and 
CD137 domains. In a Raji B-cell lymphoma model in NOD-SCID IL2R gnull (NSG) mice, 
treatment with NK-92/63.z cells but not parental NK-92 cells inhibited disease progression, 
indicating that selective cytotoxicity was retained in vivo. Conclusions. Our data demonstrate 
that it is feasible to generate CAR-engineered NK-92 cells with potent and selective 
antitumor activity. These cells may become clinically useful as a continuously expandable 
off-the-shelf cell therapeutic agent.
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Introduction
Chimeric antigen receptor (CAR)-engineered T cells targeting the B-cell differentiation 
antigen CD19 have demonstrated remarkable clinical efficacy in patients with lymphomas 
and leukemias of B-cell origin [1-7]. Natural killer (NK) cells represent another important cell 
type for adoptive immunotherapy [8, 9], but CAR-mediated retargeting of NK cells has been 
attempted less frequently and so far no clinical data for such an approach are available [10]. 
NK cells are part of the innate immune system and play an important role in cancer 
immunosurveillance [11, 12]. They do not require prior sensitization and recognition of 
peptide antigens presented in complex with MHC molecules, but are controlled in their 
activity by distinct germline-encoded cell surface receptors that allow discrimination between 
healthy and diseased tissues [13, 14]. In cancer patients, NK-cell responses are often 
impaired due to the immunosuppressive tumor microenvironment. Hence, current NK-cell 
therapies are typically based on adoptive transfer of ex vivo expanded allogeneic NK cells 
derived from a suitable donor [9, 15]. While displaying graft-versus-leukemia or graft-versus-
tumor activity, such donor-derived NK cells do not carry the risk of graft-versus-host-disease 
frequently associated with donor lymphocyte infusion of allogeneic T cells, which may also 
be a limitation of allogeneic CAR-engineered T lymphocytes [16].
Unlike primary NK cells which have a limited life span and expansion potential, the 
human NK cell line NK-92 can be continuously expanded in the presence of IL-2 in a GMP-
compliant process [17]. Safety and clinical activity of NK-92 cells as an allogeneic cell 
therapeutic has been demonstrated in early phase clinical trials in patients with advanced 
malignancies [18-20]. The feasibility of generating CD19-specific CAR NK cells has been 
investigated in preclinical studies employing both primary human NK cells as well as NK-92 
[21-23]. Thereby the use of NK-92 allows isolation and expansion of CAR-engineered cells 
from a bulk of non-transduced cells [24-26], which bypasses the problem of limited efficiency
of gene transfer into NK cells when compared to T cells [22, 27]. For primary CAR NK cells 
targeting CD19 it was previously demonstrated that by inclusion of a costimulatory protein 
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domain derived from CD137 (4-1BB) or CD244 (2B4) in the CAR in addition to CD3z,
activation and cytotoxicity were markedly enhanced in comparison to cells carrying a CD3z-
only CAR [21, 23]. In contrast, for the establishment of CD19-specific CAR NK-92 cells so far 
only first-generation CARs were employed, which utilized a murine CD3z domain for 
signaling [22, 28, 29].
To investigate the impact of different CAR designs on activation and cytotoxicity of NK-
92 cells, here we engineered the cells by lentiviral gene transfer to express CD19-specific 
CARs that harbor human CD3z (CAR 63.z) or composite CD28-CD3z or CD137-CD3z
domains (CARs 63.28.z and 63.137.z) for signaling. We analyzed in vitro cytotoxicity of the 
CAR NK-92 cells against established cancer cell lines and primary pre-B-ALL blasts, and 
dependence of cell killing on expression of the CD19 target antigen and CAR activation. Due 
to their more pronounced cytotoxicity in vitro, NK-92/63.z cells expressing a humanized first-
generation CAR were chosen for analysis of in vivo antitumor activity in comparison to 




Cells and culture conditions
Human MDA-MB453 breast carcinoma and HEK 293T cells (both ATCC, Manassas, VA) 
were propagated in DMEM (Lonza, Cologne, Germany). Human Raji and WSU-NHL 
lymphoma, BV173 leukemia and C1R-neo B-cell lymphoblastoid cells (all ATCC) were 
cultured in RPMI 1640 medium (Lonza). Media were supplemented with 10% heat-
inactivated FBS, 2 mM L-glutamine, 100 U/ml penicillin, 100 g/ml streptomycin (Life
Technologies, Darmstadt, Germany). MDA-MB453/CD19 breast carcinoma cells were 
generated by transduction with GALV pseudotyped retroviral vector encoding truncated 
human CD19 (kindly provided by Malcolm Brenner and Gianpietro Dotti, Baylor College of 
Medicine, Houston, TX) following standard protocols [30]. Primary human pre-B-ALL blasts 
were grown in Iscove's modified Dulbecco's medium (IMDM; Lonza) supplemented with 1 
µg/mL bovine insulin (Sigma-Aldrich, Taufkirchen, Germany), 50 M b-mercaptoethanol, 200 
µg/mL Fe3+-saturated human apo-transferrin (Invitrogen, Karlsruhe, Germany), 0.6% human 
serum albumin (Sanquin, Amsterdam, The Netherlands), 2.0 mM L-glutamine, and 20 µg/mL 
cholesterol [31]. Human NK-92 cells (kindly provided by NantKwest, Inc., Culver City, CA) 
were cultured in X-VIVO 10 (Lonza) containing 5% heat-inactivated human plasma (German 
Red Cross Blood Donation Service Baden-Württemberg - Hessen) and 100 IU/mL IL-2 
(Proleukin; Novartis Pharma).
Generation of CAR-expressing NK-92 cells
CARs 63.z, 63.28.z and 63.137.z consist of an immunoglobulin heavy chain signal peptide, a 
scFv fragment of CD19-specific antibody FMC63 [32], and a modified CD8a hinge region, 
either followed by CD3z transmembrane and intracellular domains (CAR 63.z), CD28 
transmembrane and intracellular domains and CD3z intracellular domain (CAR 63.28.z), or 
CD137 (4-1BB) transmembrane and intracellular domains and CD3z intracellular domain 
(CAR 63.137.z). Codon-optimized CAR sequences were synthesized (GeneArt, Thermo 
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Fisher Scientific, Braunschweig, Germany) and inserted into lentiviral transfer plasmid 
pHR'SIN-cPPT-SIEW (pSIEW) upstream of IRES and EGFP sequences [33], yielding the 
vectors pS-63.z-IEW, pS-63.28.z-IEW, and pS-63.137.z-IEW. As a control, the CAR 
signaling domains were removed from the pS-63.28.z-IEW construct by digestion with NaeI 
and religation, with the resulting pS-63.TM-IEW vector containing a premature stop codon 
following the transmembrane domain of CD28. VSV-G pseudotyped vector particles were 
produced using HEK 293T cells and NK-92 cells were transduced as described [25, 34]. 
EGFP-expressing NK-92 cells were enriched by flow cytometric cell sorting with a FACSAria 
fluorescence-activated cell sorter (BD Biosciences, Heidelberg, Germany). CAR surface 
expression in the obtained cell pools was confirmed by flow cytometry with Myc-tag-specific 
antibody (9E10; Santa Cruz, Heidelberg, Germany) using a FACSCalibur flow cytometer (BD 
Biosciences). Data were analyzed with CellQuest Pro software (BD Biosciences).
CD19 expression and cytotoxicity assays
CD19 expression on the surface of target cells was analyzed by flow cytometry using FITC-
coupled CD19-specific antibody (SJ25-C1; Invitrogen). Cytotoxicity of NK-92 cells towards 
established cancer cell lines and primary human pre-B-ALL blasts was analyzed in FACS-
based assays as described [34]. Target cells were labeled with calcein violet AM (CV) 
(Molecular Probes, Invitrogen) and incubated with effector cells at various effector to target 
(E/T) ratios for 2 h at 37°C. Then 150 L of a 1 g/mL propidium iodide (PI) solution were 
added to each sample before flow cytometric analysis in a FACSCanto II flow cytometer (BD 
Biosciences). Dead target cells were identified as CV and PI double positive. Spontaneous 
target cell lysis in the absence of NK cells was subtracted to calculate specific cytotoxicity. 
Data were analyzed using FACSDiva software (BD Biosciences).
Degranulation assay and conjugate analysis
Degranulation of NK cells upon exposure to target cells at an E/T ratio of 1:1 for 1 h at 37°C 
was analyzed as described [35], detecting surface expression of lysosomal-associated 
- 8 -
membrane protein LAMP-1 (CD107a) using BD FastImmune CD107a APC antibody (BD 
Biosciences) according to the manufacturer’s instructions. As controls, NK cells were 
stimulated with 1 g/mL phorbol 12-myristate 13-acetate (PMA) and 1 g/mL ionomycin 
(Sigma-Aldrich), or incubated without target cells. Conjugate formation and redistribution of 
cytotoxic granules were assessed by confocal laser scanning microscopy. NK cells and 
target cells were mixed at a 1:1 ratio and kept on poly-L-lysine-coated cover slips (Life 
Technologies) for 1 h at 37°C. Then the cells were fixed for 10 min with phosphate-buffered 
4% formaldehyde solution and permeabilized for 5 min with 0.1% Triton X-100 in PBS. After
washing and blocking of unspecific binding sites for 30 min with 10% FBS in PBS, the 
samples were incubated for 1 h with perforin-specific antibody (dG9; Santa Cruz 
Biotechnology) and Alexa Fluor 594-coupled anti-mouse secondary antibody (Invitrogen) in 
blocking buffer at room temperature. Nuclei were stained with DAPI (4',6-diamidino-2-
phenylindole) (Life Technologies). After washing with PBS, cells were embedded with Mowiol 
4-88 (Roth, Karlsruhe, Germany) and analyzed using a Leica SP5 confocal laser scanning 
microscope (Leica Microsystems, Wetzlar, Germany).
Cytometric bead array
Cytokine release by NK-92 cells was measured using a BD Cytometric Bead Array (CBA) 
and a BD FACSArray bioanalyzer (BD Biosciences) according to the manufacturer's 
recommendations. Briefly, 5 x 105 NK-92 cells were co-cultured for 6 h at 37°C with target 
cells at an E/T ratio of 1:1 in a total volume of 1 mL. Cytokine concentrations in supernatants 
were measured using BD CBA Flex Sets for IFN-g, IL-10, GM-CSF and MIP-1a/CCL3 (all BD 
Biosciences). Data were analyzed with BD FCAP Array software (BD Biosciences).
In vivo lymphoma model 
Raji Burkitt's lymphoma cells were transduced with VSV-G pseudotyped SEW-luc2 lentiviral 
vector encoding firefly luciferase and EGFP linked via a 2A peptide [36], and EGFP-positive 
cells were enriched by flow cytometric cell sorting. Six to 8 week old male NOD-SCID IL2R 
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gnull (NSG) mice were intravenously (i.v.) injected with 1 x 103 Raji/Luc cells. At days 3, 4, 8, 
11, 13 and 22 after tumor cell inoculation animals were treated by i.v. injection of 1 x 107 NK-
92/63.z or parental NK-92 cells. Control mice received PBS. Disease development was 
monitored by imaging with an IVIS Lumina II in vivo imaging system (Perkin Elmer, Rodgau, 
Germany) 10 min after intraperitoneal injection of 75 mg/kg of D-luciferin (Promega, 
Mannheim, Germany). For in vivo experiments all applicable guidelines for the care and use 
of animals were followed. All animal experiments were approved by the responsible 
government committee (Regierungspräsidium Darmstadt, Darmstadt, Germany).
Immunohistochemistry
Liver tissue of sacrificed mice was fixed with phosphate-buffered 4% formaldehyde solution 
(Roth) and paraffin-embedded. Sections of 3 m thickness were deparaffinized and 
hydrated, and then stained using a standardized staining protocol (Bond Polymer Refine IHC 
protocol, IHC-F; Leica Microsystems) with CD19-specific antibody (HIB19, 1:100; 
eBioscience, Frankfurt, Germany) and polymeric HRP-conjugated anti-mouse secondary 
antibody (DAB Polymer Refine Detection Kit; Leica Microsystems). Slides were then stained 
with hematoxylin and embedded in mounting medium.
Statistical Analysis
Data were analyzed by two-tailed unpaired Student’s t-test. P values < 0.05 were considered 




Lentiviral transduction of NK-92 cells results in surface expression of CD19-specific 
chimeric antigen receptors
For comparative analysis of different protein designs, we generated codon-optimized CAR 
sequences which all harbor a CD19-specific scFv fragment derived from antibody FMC63 
[32], linked to human CD3z (CAR 63.z), or composite CD28-CD3z (CAR 63.28.z) or CD137-
CD3z (CAR 63.137.z) signaling domains via a CD8a hinge region [25, 34]. A corresponding 
truncated CAR (CAR 63.TM) containing the transmembrane domain of CD28 but lacking 
intracellular signaling domains served as a control. The CAR sequences were inserted into 
the self-inactivating lentiviral vector pSIEW, where they are encoded under the control of the 
Spleen Focus Forming Virus (SFFV) promoter and coexpressed with an EGFP marker gene
(Figure 1A). VSV-G pseudotyped lentiviral vector particles were produced and used for
transduction of human NK-92 cells. CAR NK-92 cells were enriched by two rounds of flow 
cytometric cell sorting resulting in homogeneous EGFP-positive NK cell populations (Figure
1B, upper panels), with highest CAR surface expression found for NK-92/63.28.z cells, more 
moderate expression for NK-92/63.z cells and less pronounced expression for NK-92/137.z 
cells (Figure 1B, lower panels).
CAR composition influences cytotoxic activity against established cancer cells 
Cytotoxic potential and specificity of CAR NK-92 cells were first assessed using established 
human Raji and WSU-NHL lymphoma, BV173 leukemia and C1R-neo B-cell lymphoblastoid 
cells as targets that express varying levels of CD19 (Figure 2A). CD19 highly positive Raji 
and BV173 cells showed no or only moderate sensitivity to parental NK-92 cells after 2 hours 
of co-incubation, but were readily killed by NK-92/63.z, NK-92/63.28.z and NK-92/137.z cells 
(Figure 2B, left panels). Interestingly, especially at low E/T ratios of 5:1 and 1:1, NK-92/63.z 
cells displayed more potent cell killing activity than NK-92/63.28.z cells, with NK-92/137.z 
cells being the least effective of the three CAR NK cell populations. This was even more 
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apparent for intrinsically NK-sensitive WSU-NHL and C1R-neo target cells, which express 
considerably lower levels of CD19 but were also most effectively killed by NK-92/63.z cells 
(Figure 2B, right panels). Cytotoxicity of NK-92 cells expressing the second-generation CARs 
63.28.z or 63.137.z was less pronounced, in the case of C1R-neo target cells not differing 
significantly from that of parental NK-92 cells. 
Targeted cytotoxicity depends on CD19 recognition and CAR signaling
To verify that increased cytotoxicity of CAR NK-92 cells was due to CAR-mediated 
recognition of CD19, similar experiments were performed with MDA-MB453 breast 
carcinoma cells transduced with a CD19-encoding retroviral vector (MDA-MB453/CD19) 
(Figure 3A). Thereby NK-92/63.z cells again displayed most potent killing of otherwise NK-
resistant MDA-MB453/CD19 cells, with marked but less pronounced cytotoxicity observed for 
NK-92/63.28.z and NK-92/137.z cells. In contrast, CD19-negative MDA-MB453 cells were 
not lysed by any of the NK-92 derivatives, thus confirming CAR specificity. Furthermore, NK-
92/63.TM cells which express a truncated CD19-specific CAR without signaling capabilities 
failed to kill MDA-MB453/CD19 cells, demonstrating that CAR-mediated signaling is required 
to trigger lytic activity (Figure 3B). Likewise, engagement of the functional CARs 63.z, 
63.28.z and to a lesser extent 63.137.z but not of signaling-deficient CAR 63.TM induced 
CD19-dependent degranulation of NK-92 cells (Figure 3C). When analyzed by confocal 
microscopy after 1 hour of co-incubation, NK-92 cells expressing functional CARs as well as 
parental NK-92 and NK-92/63.TM cells had all formed contacts with MDA-MB453/CD19 
cells. However, only conjugate formation between NK-92/63.z and NK-92/63.28.z with MDA-
MB453/CD19 cells rapidly triggered concentration of perforin-containing cytotoxic granules at 
the immunological synapse (Figure 3D), confirming the reduced responsiveness of NK-
92/63.137.z and the lack of activation of NK-92/63.TM and parental NK-92 cells observed in 
the degranulation experiments.
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CAR 63.28.z induces high-level cytokine secretion
In addition to the release of cytotoxic granules, CAR activation in NK cells can trigger 
secretion of cytokines and chemokines [25, 26, 37]. To test cytokine production of CD19-
specific CAR NK-92 cells, we co-incubated NK-92/63.z, NK92/63.28.z and NK-92/63.137.z
cells with CD19-positive Raji lymphoma cells for 6 hours at an E/T ratio of 1:1 and analyzed 
culture supernatants using a cytometric bead array (Figure 4). Parental NK-92 and NK-
92/63.TM cells were included as controls. While all NK-92 variants secreted measurable 
levels of the chemokine MIP-1a/CCL3 after prolonged contact with Raji cells, only NK-
92/63.z and NK92/63.28.z cells produced high levels of the pro-inflammatory cytokines IFN-g
and GM-CSF. These cells also generated more pronounced levels of immunoregulatory IL-
10 than parental NK-92, NK-92/63.137.z and NK-92/63.TM cells. Of note, levels of IFN-g, 
GM-CSF and IL-10 produced by NK92/63.28.z cells were thereby considerably higher than 
those secreted by NK-92/63.z cells, despite the superior activity of the latter against Raji cells 
observed in cytotoxicity assays (see Figure 2B). 
CAR NK-92 cells lyse NK-resistant primary B-ALL blasts
Next we analyzed a panel of primary pre-B-ALL blasts previously shown to retain the
characteristics of the original tumors during long-term culture [31]. All primary target cells 
investigated expressed elevated surface levels of CD19 (Figure 5A). KW, DW and BV pre-B-
ALL cells displayed pronounced resistance to parental NK-92 cells after 2 hours of co-
incubation. In contrast, even at low E/T ratios of 5:1 and 1:1, the primary cells were readily 
killed by NK-92/63.z and NK-92/63.28.z, and to a lesser extent by NK-92/63.137.z cells 
(Figure 5B), confirming the observations made with established lymphoma and leukemia cell 
lines as targets.
NK-92/63.z cells inhibit in vivo lymphoma growth
Due to their enhanced antitumoral activity in vitro, NK-92/63.z cells were chosen for 
evaluation of the in vivo activity of CD19-specific CAR NK-92 cells in an aggressive
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lymphoma xenograft model in NOD-SCID IL2R gnull (NSG) mice. Animals were intravenously 
injected with 1 x 103 luciferase-expressing Raji cells. At days 3, 4, 8, 11, 13 and 22 after 
tumor cell inoculation, the mice were treated by intravenous injection of 1 x 107 parental NK-
92 or CAR-expressing NK-92/63.z cells. Control animals received PBS. Lymphoma 
development was monitored at frequent intervals by in vivo bioluminescence imaging (BLI) 
(Figure 6A, B). While parental NK-92 cells had little effect on tumor development in 
comparison to PBS treatment resulting until day 32 in marked lymphoma growth in liver, 
joints and lymph nodes (Figure 6A), therapy with NK-92/63.z cells was effective and 
significantly delayed disease development, with remaining lymphoma mainly restricted to 
small areas in the liver. This was confirmed by immunohistochemical analysis demonstrating 
heavy infiltration of the livers of mice treated with parental NK-92 cells or PBS with CD19-
positive lymphoma cells, while liver tissue from NK-92/63.z-treated animals showed more
confined lymphoma growth (Figure 6C).
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Discussion
In this study we generated a panel of CAR-engineered NK-92 natural killer cell variants
targeting the B-cell differentiation antigen CD19 and investigated their activity against 
lymphoma and leukemia cells in preclinical in vitro and in vivo models. Immune cells in 
cancer patients are often functionally compromised due to the immunosuppressive activity of 
the malignant cells. Hence, for adoptive cancer immunotherapy with NK cells, donor-derived 
allogeneic cells are being preferred which do not recognize tumor cells as 'self', thereby 
bypassing inhibitory signals [9, 15]. This advantage may be extended to NK-92 cells that do 
not express most of the inhibitory KIRs and phenotypically resemble activated NK cells [17, 
38]. We and others have previously described CAR-engineered NK-92 cells which target 
antigens expressed by cancer cells of solid tumor origin or hematological malignancies, 
indicating the potential utility of this approach [22, 24, 25, 34, 39-42]. In most of these cases, 
however, prototypic CD3z-based CARs were employed without additional costimulatory 
protein domains such as CD28 and CD137, which are utilized in the CD19-specific 
constructs of CAR-T cells currently in advanced stages of clinical development and crucial 
for the T cells' long-term engraftment and functionality [43].
To investigate the possible contribution of CD28 and CD137 signaling to CAR-
mediated activity of NK-92 cells, we generated CD19-specific CARs harboring the same
codon-optimized scFv antibody fragment and CD8a hinge region, either linked to human 
CD3z, or composite CD28-CD3z or CD137-CD3z signaling domains. Gene-modified NK-92 
cell lines obtained after lentiviral gene transfer and flow cytometric cell sorting displayed 
homogeneous and stable CAR surface expression, and showed high and specific cytotoxicity 
against CD19 overexpressing established lymphoma and leukemia cells that were resistant
or only moderately sensitive to parental NK-92 cells. This confirms earlier reports with NK-92 
cells expressing a CD19-specific first-generation CAR based on murine CD3z [22, 28, 29], 
and demonstrates that the human signaling domains, as expected, are functionally active. 
Importantly, NK-92/63.z, NK-92/63.28.z and NK-92/63.137.z cells even at low E/T ratios also 
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displayed marked cell killing activity against primary human pre-B-ALL blasts, which were 
completely resistant to parental NK-92 cells. Thereby recognition of CD19 and CAR 
activation were required for specific cytotoxicity as evidenced by the observed lysis of 
otherwise NK-resistant MDA-MB453 breast carcinoma cells upon ectopic expression of 
CD19, and absence of cell killing if a CD19-specific CAR without signaling domains was 
employed. Likewise, contact of NK-92/63.z and NK-92/63.28.z cells, and to a lesser extent of 
NK-92/63.137.z cells with MDA-MB453/CD19 cells triggered NK-cell degranulation, which 
was not observed with parental NK-92 and NK-92/63.TM cells.
For CD19-targeted primary NK cells expanded on K562 feeder cells expressing 
membrane-anchored IL-15 and 4-1BB ligand, inclusion of costimulatory CD137 (4-1BB) or 
CD244 (2B4) domains in the CAR in addition to CD3z was shown to enhance both, specific 
cytotoxicity and production of IFN-g and GM-CSF [21, 23]. In our study, NK-92/63.137.z cells 
were less effective than NK-92/63.z and NK-92/63.28.z in cell killing and cytokine production, 
pointing towards a differential requirement for costimulatory signals between primary NK 
cells and established NK-92. While we observed significantly increased cytokine production 
by NK-92/63.28.z in comparison to NK-92/63.z cells, there was no enhancement in cell killing 
if the CD28 domain was present. In contrast, depending on the type of target cells
cytotoxicity of NK-92/63.28.z cells was in most cases less pronounced than that of NK-
92/63.z. This may in part be explained by differences in the threshold for CAR signaling. 
CAR 63.z utilizes the endogenous transmembrane domain of CD3z, which allows formation 
of disulfide-linked CAR homodimers and heterodimers of CAR and endogenous CD3z [24, 
25, 39]. Such preformed receptor complexes may get activated more rapidly and by lower 
target antigen densities than CAR 63.28.z that utilizes the transmembrane domain of CD28 
and cannot form covalent dimers. Also sterical effects can play a role in determining the 
activation threshold of individual CARs [44]. While CARs 63.z and 63.28.z contain the same 
scFv antibody fragment and CD8a hinge domain, their different membrane anchors may 
influence flexibility and access to the target antigen.
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Due to their enhanced cytotoxic activity in vitro, NK-92/63.z cells were chosen for 
further evaluation in a Raji lymphoma xenograft model in NSG mice. While repeated 
systemic injections of parental NK-92 cells had little effect resulting in extensive lymphoma 
growth in liver, joints and lymph nodes, disease development was controlled to a large extent 
by NK-92/63.z cells demonstrating that they retained specific antitumor activity in vivo. In this 
immunodeficient mouse model analysis is restricted to direct antitumor effects of the CAR NK 
cells. Nevertheless, in a clinical setting also interaction with endogenous immune cells may 
contribute to their therapeutic activity. Thereby production of cytokines such as IFN-g, GM-
CSF and the chemokine MIP-1a (CCL3) as particularly observed after exposure of NK-
92/63.28.z cells to CD19-positive targets will likely be important for NK-mediated 
enhancement of adaptive immunity [45]. Indeed, in a recent study treatment with NK-92 cells 
expressing an ErbB2/HER2-specific CAR with CD28 and CD3z domains in addition to direct 
antitumor effects induced long-lasting endogenous antitumor immunity in an 
immunocompetent glioblastoma model [26].
As a truly off-the-shelf therapeutic, continuously expanding CAR NK-92 cells may 
become clinically useful for the treatment of cancer patients especially in cases where the 
infrastructure or suitable donors for a CAR T cell approach are not available. Our data 
demonstrate high and consistent cytotoxic activity of NK-92 cells expressing CD19-specific 
CARs that employ CD3z or CD28-CD3z signaling domains against established and primary 
B-cell lymphoma and leukemia cells, while a similar CD137-CD3z CAR was functional but 
less effective. At low E/T ratios NK-92/63.z cells displayed more pronounced cell killing than 
NK-92/63.28.z cells, while the latter secreted higher cytokine levels upon CAR triggering. 
This may contribute to direct and indirect antitumor effects and should be considered during 
further development of this approach towards clinical applications.
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Figure 1. Generation of CAR-engineered NK-92 cells. (A) Lentiviral transfer plasmids 
encoding different chimeric antigen receptors under the control of the Spleen Focus Forming 
Virus promoter (SFFV). The CAR sequences are followed by an internal ribosome entry site 
(IRES) and enhanced green fluorescent protein (EGFP) cDNA. In pS-63.z-IEW the CAR 
consists of an immunoglobulin heavy chain signal peptide (SP), a CD19-specific scFv 
antibody fragment, a Myc-tag (M), a CD8a hinge region (CD8a), and transmembrane and 
intracellular domains of CD3z (CAR 63.z). pS-63.28.z-IEW and pS-63.137.z-IEW vectors
encode similar CARs with transmembrane and intracellular domains of CD28 and the 
intracellular domain of CD3z (CAR 63.28.z), or transmembrane and intracellular domains of 
CD137 (4-1BB) and the intracellular domain of CD3z (CAR 63.137.z), respectively. (B)
Enhanced green fluorescent protein expression of sorted NK-92/63.z, NK-92/63.28.z and 
NK-92/63.137.z cells was determined by direct flow cytometry (upper panel, filled areas). 
CAR surface expression was analyzed by flow cytometry with Myc-tag-specific antibody 
(lower panel, filled areas). Parental NK-92 cells (open areas) and cells stained with an 
irrelevant isotype-matched antibody (dashed lines) served as controls.
Figure 2. Specific cytotoxicity of CAR NK cells against established lymphoma and leukemia 
cells. (A) Expression of CD19 on the surface of Raji and WSU-NHL lymphoma, BV173 
leukemia and C1R-neo B-cell lymphoblastoid cells was determined by flow cytometry with 
CD19-specific antibody (filled areas). Unstained cells served as controls (open areas). (B)
Cell killing by parental NK-92 (open circles) and CAR-expressing NK-92/63.z (filled circles), 
NK-92/63.28.z (open triangles) and NK-92/63.137.z cells (filled triangles) was investigated in 
FACS-based cytotoxicity assays after co-incubation with target cells for 2 h at the indicated 
E/T ratios. Mean values ± SEM are shown; n=4. *, p < 0.05; ns, p ³ 0.05.
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Figure 3. Dependence of target cell killing on CAR-mediated NK-cell activation. (A) To 
confirm specificity, cytotoxicity of parental NK-92 (open circles) and CAR-expressing NK-
92/63.z (filled circles), NK-92/63.28.z (open triangles) and NK-92/63.137.z cells (filled 
triangles) was investigated after co-incubation for 2 h at the indicated E/T ratios with CD19-
negative MDA-MB453 human breast carcinoma cells and MDA-MB453/CD19 cells 
transduced with a CD19-encoding retroviral vector as targets. (B) Cytotoxicity of CAR NK 
cells against MDA-MB453/CD19 cells at an E/T ratio of 10:1 was compared to that of NK-
92/63.TM cells which express a truncated CD19-specific CAR without signaling domains. (C)
Degranulation of NK-92/63.z, NK92/63.28.z and NK-92/63.137.z upon activation by CD19-
expressing cancer cells was analyzed by flow cytometry determining CD107a surface 
expression after 5 h of co-culture with MDA-MB453 or MDA-MB453/CD19 target cells at an 
E/T ratio of 1:1. Parental NK-92 and NK-92/63.TM cells were included for comparison. NK 
cells stimulated with phorbol 12-myristate 13-acetate (PMA) and ionomycin (Iono) served as 
controls. Mean values ± SEM are shown in panels a, b, c; n=5. **, p < 0.01; ns, p ³ 0.05. (D)
Conjugate formation between CAR NK cells and MDA-MB453/CD19 target cells was 
investigated by confocal microscopy. Tumor (T) and CAR NK-92 (N) cells were co-incubated 
for 1 h. Cells were stained for perforin (red) to identify cytotoxic granules. Nuclei were labeled 
with DAPI (blue). Parental NK-92 and NK-92/63.TM cells served as controls. Scale bar: 10 
m.
Figure 4. Secretion of cytokines by CAR NK cells upon activation by CD19-expressing 
lymphoma cells. 5 x 105 NK-92, NK-92/63.z, NK92/63.28.z, NK-92/63.137.z or NK-92/63.TM
cells were incubated for 6 h with Raji lymphoma cells at an E/T ratio of 1:1. Supernatants 
were collected and the levels of (A) IFN-g, (B) GM-CSF, (C) MIP-1a/CCL3, and (D) IL-10 
were measured using a cytometric bead array. NK cells kept without target cells were 
included as controls. Mean values ± SEM are shown; n=3. **, p < 0.01; *, p < 0.05; ns, p ³
0.05.
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Figure 5. Killing of pre-B-ALL blasts by CAR NK cells. (A) Expression of CD19 on the surface 
of primary pre-B-ALL blasts from three different patients (KW, DW, BV) was determined by 
flow cytometry with CD19-specific antibody (filled areas). Unstained cells served as controls 
(open areas). (B) Specific lysis of pre-B-ALL blasts by parental NK-92 (open circles) and 
CAR-expressing NK-92/63.z (filled circles), NK-92/63.28.z (open triangles) and NK-
92/63.137.z cells (filled triangles) was investigated in FACS-based cytotoxicity assays after 
co-incubation with target cells for 2 h at the indicated E/T ratios. Mean values ± SEM are 
shown; n=3. ns, p ³ 0.05.
Figure 6. Inhibition of in vivo lymphoma growth by CD19-specific CAR NK-92 cells. NSG 
mice were intravenously injected with 1 x 103 Raji/Luc lymphoma cells. At days 3, 4, 8, 11, 13 
and 22 after tumor cell inoculation, the animals were treated by intravenous injection of 1 x 
107 parental NK-92 or CAR-expressing NK-92/63.z cells. Control mice received PBS. (A)
Lymphoma development was monitored by in vivo bioluminescence imaging. Images taken 
at day 32 of the experiment are shown (exposure time of 1 sec). (B) Average radiance values 
measured over time. Mean values ± SEM are shown; n=4; **, p < 0.01. (C) Sections of liver 
tissues from mice treated with NK-92/63.z, parental NK-92 cells or PBS were stained with 
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